CorMedix Inc
CRMD
View Detailed Chart
14.350USD
+0.210+1.49%
Close 08/28, 16:00（ET）Quotes delayed by 15 min
1.07BMarket Cap
62.33P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.49%
5 Days
+5.83%
1 Month
+19.78%
6 Months
+38.51%
Year to Date
+77.16%
1 Year
+138.37%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-08-27Key Insights
The company's fundamentals are relatively very healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a very weak market performance, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
7
analysts
Buy
Current Rating
19.833
Target Price
+40.26%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 66363.08% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.47M.
Overvalued
The company’s latest PE is 17.67, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.40M shares, decreasing 22.55% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.31M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.57.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Ticker SymbolCRMD
CompanyCorMedix Inc
CEOMr. Joseph Todisco
Websitehttps://cormedix.com/
Related Instruments
-0.30%
-0.76%
-0.07%
+0.08%
-0.33%
-1.02%
-0.58%
-0.82%
-1.87%
-1.19%
-0.34%
+0.76%
-1.57%
-0.21%
-0.36%
-1.18%
+0.09%
-0.37%
-1.25%
-0.41%
